T. Rowe Price Associates’s Senti Biosciences Holdings SNTI Stock Holding History

T. Rowe Price Associates’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-314,712	Closed	-$1.34M	–	2929
2023 Q3	$1.34M	Sell	314,712 -24,621	-7%	-$169K	﹤0.01%	1658
2023 Q2	$2.12M	Sell	339,333 -7,454	-2%	-$72.7K	﹤0.01%	1454
2023 Q1	$4.09M	Sell	346,787 -8,615	-2%	-$134K	﹤0.01%	1232
2022 Q4	$5.01M	Sell	355,402 -46,146	-11%	-$1.13M	﹤0.01%	1188
2022 Q3	$8.71M	Buy	401,548 +42,589	+12%	+$839K	﹤0.01%	1090
2022 Q2	$7M	Buy	358,959 +348,892	+3,466%	+$28M	﹤0.01%	1379
2022 Q1	$994K	Hold	10,067	–	–	﹤0.01%	2013
2021 Q4	$993K	Sell	10,067 -289,933	-97%	-$28.9M	﹤0.01%	2043
2021 Q3	$29.8M	Hold	300,000	–	–	﹤0.01%	1183
2021 Q2	$29.8M	Buy	+300,000	New	+$29.9M	﹤0.01%	1201

Other funds holding SNTI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

8GI

8VC GP I Austin, Texas $42.8M AUM 15.67% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intel Corp Santa Clara, California $621M AUM 34.06% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

T. Rowe Price Associates's SNTI Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Senti Biosciences Holdings (SNTI) in Q4 2023, closing a stake of 314,712 shares — an estimated $1.34M sold.

T. Rowe Price Associates first reported a position in SNTI in Q2 2021 and held it in 10 quarters. The position peaked at $29.8M in Q3 2021. 25 funds tracked by Wall St. Rank hold SNTI as of Q4 2023.

T. Rowe Price Associates reported no remaining Senti Biosciences Holdings position as of Q4 2023 after selling out during the quarter.
T. Rowe Price Associates sold 314,712 Senti Biosciences Holdings shares in Q4 2023, an estimated $1.34M.
T. Rowe Price Associates first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 10 quarters.
T. Rowe Price Associates's Senti Biosciences Holdings position peaked at $29.8M in Q3 2021.
25 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.